Royalty Report: Drugs, Pain – Collection: 233488

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233488

License Grant
The Licensor and Chinese Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in United States and China.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
Oliceridine is an opioid drug that is under evaluation in human clinical trials for the intravenous treatment of severe acute pain.

IPSCIO Record ID: 232897

License Grant
The Licensor and Korean Licensee entered into an exclusive licensing agreement for the development and commercialization of Oliceridine in South Korea.
License Property
Oliceridine is a G protein biased ligand of the µ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 183240

License Grant
The Licensor announced the signing of exclusive global license and supply agreements with the Licensee for three captisol enabled programs, one of which is Meloxicam
License Property
Captisol is a modified cyclodextrin preparation, designed to optimize the solubility and stability of drugs.

Captisol-enabledâ„¢ Meloxicam is an intravenous (IV) and intramuscular (IM) version of meloxicam specifically formulated to provide an option for hospital patients suffering from acute post-surgery, trauma and cancer pain following use of IV/IM NSAIDs and in place of or delaying use of IV/IM opioids, which put patients at risk for addiction, respiratory depression, sedation and constipation. Mobic (meloxicam) is currently only available in an oral formulation.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.  IM/IV CE Meloxicam is for patients with acute pain

Field of Use
This agreement is for the drug industry.

IPSCIO Record ID: 369250

License Grant
Licensor grants, as of the date of execution of this Agreement, a personal, perpetual, exclusive and nontransferable right and license under the Product Intellectual Property, to make, have made, use, offer to sell, sell and import Products in the Field in the Territory for the sole purpose of completing the Pre-Launch Marketing Activities prior to the transfer of the NDA, and, thereafter a transferable license for the sole purpose of Commercialization of the Product in the Territory.
License Property
Licensor owns certain Intellectual Property Rights related to Intravenous Tramadol HCl, the Product, and is seeking approval from the FDA for the marketing and sale of products that incorporates or is comprised of Tramadol.

The Product shall mean Intravenous Tramadol HC1.

The patent is for Intravenous Administration of Tramadol.

Field of Use
Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets.  Tramadol is used to treat moderate to severe pain in adults.

IPSCIO Record ID: 3265

License Grant
The Licensor will grant the Licensee a non-exclusive, royalty-bearing future license to the Licensor Patent and other current and future Orange Book listable patents to market, manufacture and sell a generic version of Oxecta® in the United States.

The Licensee's license becomes effective January 1, 2022, approximately 23 months prior to the expected expiration of the Licensor Patent.

License Property
OXECTA is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

In June 2011, the U.S. Food and Drug Administration approved Oxecta® (oxycodone HC1 tablets) which incorporates the Aversion® technology. Oxecta® is an abuse-deterrent opioid analgesic formulation.

Field of Use
The Field of Use apply to the healthcare industry.

IPSCIO Record ID: 262471

License Grant
The Company granted Licensee the right to commercialize the NUCYNTA franchise of pain products in the United States.  Pursuant to the Commercialization Agreement, Licensee assumed all commercialization responsibilities for the NUCYNTA franchise effective January 9, 2018, including sales and marketing. The Company also agreed to provide services to Licensee, including to arrange for the supply of NUCYNTA products by the Company’s existing contract manufacturing organizations (“CMOs”) (the “Facilitation Services”).
License Property
NUCYNTA ER (Tapentadol Extended Release Tablets) and NUCYNTA IR (NUCYNTA) (Tapentadol) is an extended release version of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and for which alternate treatment options are inadequate. NUCYNTA is an immediate release version of tapentadol that is indicated for the management of moderate to severe acute pain in adults.
Field of Use
This Agreement pertains to the drug industry relating to pain management.

IPSCIO Record ID: 209509

License Grant
Licensor grants the exclusive right and license, with the right to sublicense, under all Licensor Intellectual Property to make, have made, use, import, offer to sell, sell, and have sold, Compound and Products in the Field in the Territory.
License Property
Licensor is the owner of a compound identified as DPl-125, as well as certain intellectual property related to the compound.

'Compound' will mean the Delta/Mu Opioid Receptor Agonist compound known as DPI-125.

Field of Use
Licensee is the owner of certain proprietary controlled drug delivery systems. This agreement is for the field of Delta/Mu Opioid Receptor Agonists.

IPSCIO Record ID: 285945

License Grant
The Parties agreed to amend the agreement that restructured the milestone payments and the warrant agreement.
License Property
IV meloxicam –  This product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor for the management of moderate to severe pain.

V meloxicam is a non-opioid candidate for pain reduction.

Field of Use
Intravenous meloxicam for the treatment of moderate to severe acute pain.

IPSCIO Record ID: 203524

License Grant
Licensor grants an exclusive, except as to Licensor for internal research purposes only and not for clinical development, license under Know How, the Licensed Patents arid the Process Licensed Patents, to develop, obtain Regulatory Approval for, use, make, have made, import, sell, and offer for sale New Compounds and New Products in the Territory.
License Property
The patents, related foreign equivalents and know-how relate to peripherally selective opioid antagonists.

The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.

The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.

Field of Use
The Field of Use means all uses as a Peripherally Selective Opioid Receptor Antagonist, where the term Peripherally Selective Opioid Receptor Antagonist shall mean a chemical entity that has a selectivity ratio of greater than 20 upon parenteral administration as measured by the ED-50 for antagonism of analgesia in the mouse writhing test in morphine-naive mice divided by the ED-50 for precipitation of diarrhea in the morphine-dependent mice test.

Licensee is developing  alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications.  Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.